SARS-CoV-2 seroprevalence among parturient women in Philadelphia.
Sci Immunol
; 5(49)2020 07 29.
Artículo
en Inglés
| MEDLINE | ID: covidwho-690482
ABSTRACT
Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important for determining SARS-CoV-2 exposures within both individuals and populations. We validated a SARS-CoV-2 spike receptor binding domain serological test using 834 pre-pandemic samples and 31 samples from COVID-19 recovered donors. We then completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate exposure to SARS-CoV-2 within the community.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Complicaciones Infecciosas del Embarazo
/
Infecciones por Coronavirus
/
Disparidades en el Estado de Salud
/
Betacoronavirus
/
Anticuerpos Antivirales
Tipo de estudio:
Estudio de cohorte
/
Estudios diagnósticos
/
Estudio observacional
/
Estudio pronóstico
País/Región como asunto:
America del Norte
Idioma:
Inglés
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Sciimmunol.abd5709
Similares
MEDLINE
...
LILACS
LIS